Medical devices firm Sensus Healthcare Q3 revenue beats estimates on higher FDA treatment volumes

Sensus Healthcare

06/11/2025 22:10

Overview

Sensus Healthcare Q3 2025 revenue of $6.9 mln beats analyst expectations

Net loss for Q3 2025 was $0.9 mln, reflecting operational challenges

Adjusted EBITDA for Q3 2025 missed analyst estimates

Outlook

Company sees strong interest internationally following MDSAP certification

CMS coding expected to strengthen SRT adoption and reimbursement certainty

Result Drivers

INCREASED TREATMENT VOLUME - FDA treatment volumes rose 20% over the second quarter, reflecting growing adoption

INTERNATIONAL EXPANSION - Shipped 16 SRT systems, including three to China, and preparing for broader expansion

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$6.88 mln
$6.25 mln (5 Analysts)
Q3 Net Income
-$943,000
Q3 Adjusted EBITDA
Miss
-$2.40 mln
-$485,000 (2 Analysts)
Q3 Basic EPS
-$0.06
Q3 Operating Expenses
$5.28 mln
Q3 Pretax Profit
-$2.41 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Sensus Healthcare Inc is $8.00, about 53.9% above its November 5 closing price of $3.69

The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release: ID:nBw4Cy8Dqa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)